OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany
Open Access
- 27 June 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 13, 913616
- https://doi.org/10.3389/fneur.2022.913616
Abstract
Background: Ozanimod, a sphingosine 1-phosphate receptor 1 and 5 modulator, was approved as a disease-modifying therapy for active relapsing-remitting multiple sclerosis (RRMS) in 2020 and for active ulcerative colitis in 2021. Long-term, real-world studies in a nonselective population are needed. OzEAN is an ongoing study to assess the real-world effectiveness, safety, and persistent use of ozanimod and its impact on quality of life (QoL) in patients with RRMS over a 5-year period. Methods: This prospective, noninterventional, postmarketing authorization study will enroll ~1300 patients (≥ 18 years of age) with active RRMS. The decision to initiate ozanimod must have been made before and independent from study participation. Enrollment began in March 2021. Recruitment is ongoing and will last for 36 months across 140 sites in Germany. Treatment-naive patients or those having prior experience with a disease-modifying therapy receive oral ozanimod 0.92 mg/day after an initial dose escalation, per the summary of product characteristics recommendations, for up to 60 months. Persistence with ozanimod treatment (primary endpoint) is assessed at month 60. Secondary endpoints include additional physician-reported outcomes (persistence at earlier time points, annualized relapse rate, Expanded Disability Status Scale score, cognition [Symbol Digit Modalities Test], and incidence of adverse events), and patient-reported outcomes (PROs) assessing patient satisfaction, adherence, and treatment modalities (Treatment Satisfaction Questionnaire for Medication, v1.4), disability (United Kingdom Neurological Disability Rating Scale), QoL (MSQOL-54 questionnaire), fatigue (Fatigue Scale for Motor and Cognitive Functions), and health economics (Work Productivity and Activity Impairment Questionnaire for Multiple Sclerosis [German v2.1]; Multiple Sclerosis Health Resource Survey, v3.0). A Multiple Sclerosis Documentation System with an internet-based e-health portal allows patients to view files and complete questionnaires. A safety follow-up will occur 3–8 months after the last ozanimod dose for patients who discontinue treatment early. Long-term results are anticipated after study completion in 2029. Yearly interim analyses are planned after enrollment has reached 25%. Conclusion: This is the first long-term, real-world study of ozanimod in patients with RRMS and, to our knowledge, the first noninterventional study utilizing a patient portal. These data will add to the safety/efficacy profile of ozanimod demonstrated in phase 3 trials.This publication has 38 references indexed in Scilit:
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities TestMultiple Sclerosis Journal, 2009
- The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigueMultiple Sclerosis Journal, 2009
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic diseaseHealth and Quality of Life Outcomes, 2004
- The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosisMultiple Sclerosis Journal, 1999
- A 12-Item Short-Form Health SurveyMedical Care, 1996
- A health-related quality of life measure for multiple sclerosisQuality of Life Research, 1995
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993
- Rating neurologic impairment in multiple sclerosisNeurology, 1983